Advertisement

Hormones

, Volume 11, Issue 3, pp 272–289 | Cite as

Steroid hormones interrelationships in the metabolic syndrome: An introduction to the ponderostat hypothesis

  • Marià Alemany
Review

Key words

Androgens Estrogens Gluco-corticoids Metabolic syndrome Obesity Ponderostat 

References

  1. 1.
    Vague J, 1956 The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4: 20–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Hattori K, Numata N, Ikoma M, Matsuzaka A, Danielson RR, 1991 Sex differences in the distribution of subcutaneous and internal fat. Hum Biol 63: 53–63.PubMedGoogle Scholar
  3. 3.
    Starcke S, Vollmer G, 2006 Is there an estrogenic component in the metabolic syndrome. Genes Nutr 1: 177–188.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Yanase T, Fan WQ, Kyoya K, Min L, Takayanagi R, Kato S, Nawata H, 2008 Androgens and metabolic syndrome: Lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 109: 254–257.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES, 2004 Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53: 1195–1200.PubMedCrossRefGoogle Scholar
  6. 6.
    Reaven G, 2004 The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metabol Clin North Am 33: 283–303.CrossRefGoogle Scholar
  7. 7.
    Maury E, Brichard SM, 2010 Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Vidal H, 2003 Obésité et inflammation: les adipocytokines. Ann Endocrinol 64: S40–S44.Google Scholar
  9. 9.
    O’Rourke RW, 2009 Molecular mechanisms of obesity and diabetes: At the intersection of weight tregulation, inflammation, and glucose homeostasis. World J Surg 33: 2007–2013.PubMedCrossRefGoogle Scholar
  10. 10.
    Miranda PJ, DeFronzo RA, Califf RM, Guyton JR, 2005 Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am Heart J 149: 33–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Potenza MV, Mechanick JI, 2009 The metabolic syndrome: Definition, global impact, and pathophysiology. Nutr Clin Pract 24: 560–577.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan NM, 1989 The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149: 1514–1520.PubMedGoogle Scholar
  13. 13.
    Bosello O, Zamboni M, 2000 Visceral obesity and metabolic syndrome. Obes Rev 1: 47–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Hayes L, Pearce MS, Firbank MJ, Walker M, Taylor R, Unwin NC, 2010 Do obese but metabolically normal women differ in intra-abdominal fat and physical activity levels from those with the expected metabolic abnormalities? A cross-sectional study. BMC Publ Hlth 10: 723.CrossRefGoogle Scholar
  15. 15.
    Messier V, Karelis AD, Prud’homme D, Primeau V, Brochu M, Rabasa-Lhoret R, 2010 Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity 18: 911–917.PubMedCrossRefGoogle Scholar
  16. 16.
    Pascot A, Després JP, Lemieux I, et al, 2000 Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 43: 1126–1135.PubMedCrossRefGoogle Scholar
  17. 17.
    Stefan N, Kantartzis K, Machann J, et al, 2008 Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609–1616.PubMedCrossRefGoogle Scholar
  18. 18.
    Esposito K, Nicoletti G, Giugliano D, 2002 Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest 25: 646–649.PubMedCrossRefGoogle Scholar
  19. 19.
    Karelis AD, 2008 Metabolically healthy but obese individuals. Lancet 372: 1281–1283.PubMedCrossRefGoogle Scholar
  20. 20.
    Marques-Vidal P, Pécoud A, Hayoz D, et al, 2010 Normal weight obesity: Relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 20: 669–675.PubMedCrossRefGoogle Scholar
  21. 21.
    Romero-Corral A, Somers VK, Sierra-Johnson J, et al, 2010 Normal weight obesity: a risk factor for cardio-metabolic dysregulation and cardiovascular mortality. Eur Heart J 31: 737–746.PubMedCrossRefGoogle Scholar
  22. 22.
    Erlingsson S, Herard S, Leinhard OD, et al, 2009 Men develop more intraabdominal obesity and signs of the metabolic syndrome after hyperalimentation than women. Metabolism 58: 995–1001.PubMedCrossRefGoogle Scholar
  23. 23.
    Catalano KJ, Stefanovski D, Bergman RN, 2010 Critical role of the mesenteric depot versus other intra-abdominal adipose depots in the development of insulin resistance in young rats. Diabetes 59: 1416–1423.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Chapados N, Collin P, Imbeault P, Corriveau P, Lavoie JM, 2008 Exercise training decreases in vitro stimulated lipolysis in a visceral (mesenteric) but not in the retroperitoneal fat depot of high-fat-fed rats. Br J Nutr 100: 518–525.PubMedCrossRefGoogle Scholar
  25. 25.
    Ebal E, Cavalié H, Michaux O, Lac G, 2008 Visceral fat and total body fat mass correlate differently with hormones in rat. Pathol Biol 56: 283–285.PubMedCrossRefGoogle Scholar
  26. 26.
    Marin P, Björntorp P, 1993 Endocrine metabolic pattern and adipose tissue distribution. Horm Res 39: 81–85.PubMedGoogle Scholar
  27. 27.
    Gower BA, Muñoz J, Desmond R, Hilario-Hailey T, Jiao XX, 2006 Changes in intra-abdominal fat in early postmenopausal women: Effecs of hormone use. Obesity 14: 1046–1055.PubMedCrossRefGoogle Scholar
  28. 28.
    Bryzgalova G, Lundholm L, Portwood N, et al, 2008 Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. Am J Physiol 295: E904–E912.Google Scholar
  29. 29.
    Pelleymounter MA, Baker MB, McCaleb M, 1999 Does estradiol mediate leptin’s effects on adiposity and body weight? Am J Physiol 276: E955–E963.PubMedCrossRefGoogle Scholar
  30. 30.
    Björntorp P, 1987 Classification of obese patients and complications related to the distribution of surplus fat. Am J Clin Nutr 45: 1120–1125.PubMedCrossRefGoogle Scholar
  31. 31.
    Vague J, 1947 La différenciation sexuelle facteur déterminant des formes de l’obésité. Presse Med 55: 339–340.PubMedGoogle Scholar
  32. 32.
    Trémollieres FA, Pouilles JM, Ribot CA, 1996 Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol 175: 1594–1600.PubMedCrossRefGoogle Scholar
  33. 33.
    Casson PR, Elkind-Hirsch KE, Buster JE, Homsby PJ, Carson SA, Snabes MC, 1997 Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 90: 995–998.PubMedCrossRefGoogle Scholar
  34. 34.
    Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C, 2004 Androgens and bone. Endocr Rev 25: 389–425.PubMedCrossRefGoogle Scholar
  35. 35.
    Tracz MJ, Sideras K, Bolona ER, et al, Clinical review: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91: 2011–2016.Google Scholar
  36. 36.
    Valsamakis G, Chetty R, Anwar A, Banerjee AK, Barnett A, Kumar S, 2004 Association of simple anthropometric measures of obesity with visceral fat and the metabolic syndrome in male Caucasian and Indo-Asian subjects. Diabet Med 21: 1339–1345.PubMedCrossRefGoogle Scholar
  37. 37.
    Rebuffé-Scrive M, Marin P, Björntorp P, 1991 Effect of testosterone on abdominal adipose tissue in men. Int J Obesity 15: 791–795.Google Scholar
  38. 38.
    Blouin K, Richard C, Bélanger C, et al, 2003 Local androgen inactivation in abdominal visceral adipose tissue. J Clin Endocrinol Metab 88: 5944–5950.PubMedCrossRefGoogle Scholar
  39. 39.
    Blouin K, Richard C, Brochu G, et al, 2006 Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 191: 637–649.PubMedCrossRefGoogle Scholar
  40. 40.
    Kapoor D, Goodwin E, Channer KS, Jones TH, 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154: 899–906.PubMedCrossRefGoogle Scholar
  41. 41.
    Gould DC, Amoroso P, Kirby RS, 2006 Hypoandrogen-metabolic syndrome: A significant issue for men’s health. BJU Int 98: 494–496.PubMedCrossRefGoogle Scholar
  42. 42.
    Hamilton EJ, Gianatti E, Strauss BJ, et al, 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 74: 377–383.CrossRefGoogle Scholar
  43. 43.
    Akishita M, Fukai S, Hashimoto M, et al, 2010 Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 33: 587–591.PubMedCrossRefGoogle Scholar
  44. 44.
    Tchernof A, Labrie F, 2004 Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Giagulli VA, Kaufman JM, Vermeulen A, 1994 Pathogenesis of the Decreased Androgen Levels in Obese Men. J Clin Endocrinol Metab 79: 997–1000.PubMedGoogle Scholar
  46. 46.
    Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G, 2000 Decreased androgen levels in massively obese men may be associated with impaired fuction of the gonadostat. Int J Obesity 24: 1433–1437.CrossRefGoogle Scholar
  47. 47.
    Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB, 2006 Low sex hormone-binding globulin, total testosterone, and symptomatic andro-gen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843–850.PubMedCrossRefGoogle Scholar
  48. 48.
    Li CY, Giles WH, Ford ES, Liu SM, Li BY, 2010 Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabet Care 33: 1618–1624.CrossRefGoogle Scholar
  49. 49.
    Matsumoto AM, Bremner WJ, 2004 Serum testosterone assays. Accuracy matters. J Clin Endocrinol Metab 89: 520–524.PubMedCrossRefGoogle Scholar
  50. 50.
    Lea OA, Støa KF, 1972 The binding of testosterone to different serum proteins: A comparative study. Journal of Steroid Biochemistry 3: 409–419.PubMedCrossRefGoogle Scholar
  51. 51.
    Blouin K, Després JP, Couillard C, et al, 2005 Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54: 1034–1040.PubMedCrossRefGoogle Scholar
  52. 52.
    Cleland WH, Simpson ER, Mendelson CR, 1985 Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 60: 174–177.PubMedCrossRefGoogle Scholar
  53. 53.
    Brind J, Strain G, Miller L, Zumoff B, Vogelman J, Orentreich N, 1990 Obese men have elevated plasma levels of estrone sulfate. Int J Obesity 14: 483–486.Google Scholar
  54. 54.
    Cohen PG, 1999 The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypoth 52: 49–51.CrossRefGoogle Scholar
  55. 55.
    Zumoff B, Miller LK, Strain GW, 2003 Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52: 1126–1128.PubMedCrossRefGoogle Scholar
  56. 56.
    Schaller GB, 1964 The year of the gorilla, Chicago: University of Chicago Press.Google Scholar
  57. 57.
    Gesta S, Bluher M, Yamamoto Y, et al, 2006 Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Nat Acad Sci USA 103: 6676–6681.PubMedCrossRefGoogle Scholar
  58. 58.
    Shen W, Punyanitya M, Silva AM, et al, 2009 Sexual dimorphism of adipose tissue distribution across the lifespan: a cross-sectional whole-body magnetic resonance imaging study. Nutr Metab 6: 17.CrossRefGoogle Scholar
  59. 59.
    Cowell CT, Briody J, Lloyd-Jones S, Smith C, Moore B, Howman-Giles R, 1997 Fat distribution in children and adolescents - the influence of sex and hormones. Horm Res 48: 93–100.PubMedCrossRefGoogle Scholar
  60. 60.
    Labayen I, Moreno LA, Blay MG, et al, 2006 Early programming of body composition and fat distribution in adolescents. J Nutr 136: 147–152.PubMedCrossRefGoogle Scholar
  61. 61.
    Perfetto F, Tarquini R, Cornélissen G, et al, 2004 Circadian phase difference of leptin in android versus gynoid obesity. Peptides 25: 1297–1306.PubMedCrossRefGoogle Scholar
  62. 62.
    Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS, 1997 Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 99: 391–395.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Ring LE, Zeltser LM, 2010 Disruption of hypothalamic leptin signaling in mice leads to early-onset obesity, but physiological adaptations in mature animals stabilize adiposity levels. J Clin Invest 120: 2931–2941.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Goodarzi MO, Azziz R, 2006 Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocr Metab 20: 193–205.CrossRefGoogle Scholar
  65. 65.
    Gilling-Smith C, Willis DS, Beard RW, Franks S, 1994 Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79: 1158–1165.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Ducluzeau PH, Laville M, Vidal H, Pugeat M, 2001 Résistance à l’insuline et syndrome des ovaires poly-kystiques. Diabete Metabol 27: S7–S12.Google Scholar
  67. 67.
    Orio F, Palomba S, Cascella T, et al, 2003 Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2619–2623.PubMedCrossRefGoogle Scholar
  68. 68.
    Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C, 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89: 5592–5596.PubMedCrossRefGoogle Scholar
  69. 69.
    Meyer C, McGrath BP, Teede HJ, 2005 Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90: 5711–5716.PubMedCrossRefGoogle Scholar
  70. 70.
    Pasquali R, Gambineri A, Pagotto U, 2006 The impact of obesity on reproduction in women with polycystic ovary syndrome. Br J Obstet Gynaecol 113: 1148–1159.CrossRefGoogle Scholar
  71. 71.
    Attaoua R, El Mkadem SA, Radian S, et al, 2008 FTO gene associated to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 373: 230–234.PubMedCrossRefGoogle Scholar
  72. 72.
    Vignesh JP, Mohan V, 2007 Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med 53: 128–134.PubMedCrossRefGoogle Scholar
  73. 73.
    Kumar A, Woods KS, Bartolucci AA, Azziz R, 2005 Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol 62: 644–649.CrossRefGoogle Scholar
  74. 74.
    Gilling-Smith C, Story H, Rogenrs V, Franks S, 1997 Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47: 93–99.CrossRefGoogle Scholar
  75. 75.
    Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG, 2003 Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 52: 713–719.PubMedCrossRefGoogle Scholar
  76. 76.
    Moll E, van der Veen F, van Wely M, 2007 The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Up 13: 527–537.CrossRefGoogle Scholar
  77. 77.
    Essah PA, Wickham EP, Nestler JE, 2007 The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50: 205–225.PubMedCrossRefGoogle Scholar
  78. 78.
    Lankarani M, Valizadeh N, Heshmat R, Peimani M, Sohrabvand F, 2009 Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Gynecol Endocrinol 25: 504–507.PubMedCrossRefGoogle Scholar
  79. 79.
    Bhattacharya SM, 2010 Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol 26: 516–520.PubMedCrossRefGoogle Scholar
  80. 80.
    Gould DC, Kirby RS, Amoroso P, 2007 Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract 61: 341–344.PubMedCrossRefGoogle Scholar
  81. 81.
    Kaplan SA, Meehan AG, Shah A, 2006 The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176: 1524–1527.PubMedGoogle Scholar
  82. 82.
    Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M, 2011 Testosterone and metabolic syndrome: A metaanalysis study. J Sex Med 8: 272–283.PubMedCrossRefGoogle Scholar
  83. 83.
    Howard JM, 2007 Common factor of cancer and the metabolic syndrome may be low DHEA. Ann Epidemiol 17: 270.PubMedCrossRefGoogle Scholar
  84. 84.
    Charlton M, Angulo P, Chalasani N, et al, 2008 Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatol 47: 484–492.CrossRefGoogle Scholar
  85. 85.
    Korhonen S, Hippeläinen M, Vanhala M, Heinonen S, Niskanen L, 2003 The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 79: 1327–1334.PubMedCrossRefGoogle Scholar
  86. 86.
    Rodriguez A, Muller DC, Metter EJ, et al, 2007 Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92: 3568–3572.PubMedCrossRefGoogle Scholar
  87. 87.
    Corbould A, 2008 Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diab Metab Res Rev 24: 520–532.CrossRefGoogle Scholar
  88. 88.
    Alexandre C, 2005 Androgens and bone metabolism. Joint Bone Spine 72: 202–206.PubMedCrossRefGoogle Scholar
  89. 89.
    Mauras N, 2006 Growth hormone and testosterone: Effects on whole body metabolism and skeletal muscle in adolescence. Horm Res 66: 42–48.Google Scholar
  90. 90.
    Ophoff J, van Proeyen K, Callewaert F, et al, 2009 Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 150: 3558–3566.PubMedCrossRefGoogle Scholar
  91. 91.
    Ruzzin J, Wagman AS, Jensen J, 2005 Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 48: 2119–2130.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Natsui K, Tanaka K, Suda M, et al, 2006 High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporosis Int 17: 105–108.CrossRefGoogle Scholar
  93. 93.
    Schakman O, Gilson H, Kalista S, Thissen JP, 2009 Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 72: 36–41.PubMedCrossRefGoogle Scholar
  94. 94.
    Shamlian T, Cole MG, 2006 Androgen treatment of depressive symptoms in older men: A systematic review of feasibility and effectiveness. Can J Psychiat 51: 295–299.CrossRefGoogle Scholar
  95. 95.
    Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M, 2009 Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract 15: 289–305.PubMedCrossRefGoogle Scholar
  96. 96.
    Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY, 2010 Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 7: 2572–2582.PubMedCrossRefGoogle Scholar
  97. 97.
    Kalynchuk LE, Gregus A, Boudreau D, Perrot-Sinal TS, 2004 Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav Neurosci 118: 1365–1377.PubMedCrossRefGoogle Scholar
  98. 98.
    Burke HM, Davis MC, Otte C, Mohr DC, 2005 Depression and cortisol responses to psychological stress: A meta-analysis. Psychoneuroendocrinology 30: 846–856.PubMedCrossRefGoogle Scholar
  99. 99.
    Zhao Y, Ma R, Shen J, Su H, Xing DM, Du LJ, 2008 A mouse model of depression induced by repeated corticosterone injections. Eur J Pharmacol 581: 113–120.PubMedCrossRefGoogle Scholar
  100. 100.
    Killinger DW, Strutt BJ, Roncari DA, Khalil MW, 1995 Estrone formation from dehydroepiandrosterone in cultured human breast adipose stromal cells. J Steroid Biochem Mol Biol 52: 195–201.PubMedCrossRefGoogle Scholar
  101. 101.
    Schwarz HP, 1990 Conversion of dehydroepiandroster-ones sulfate (DHEA-S) to estrogens and testosterone in young nonpregnant women. Horm Metabol Res 22: 309–310.CrossRefGoogle Scholar
  102. 102.
    Favre J, Gao J, Henry JP, et al, 2010 Endothelial estrogen receptor a plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/ reperfusion. Arterioscler Thromb Vasc Biol 30: 2562–2567.PubMedCrossRefGoogle Scholar
  103. 103.
    Xu Y, Armstrong SJ, Arenas IA, Pehowich DJ, Davidge ST, 2004 Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. Am J Physiol 287: H165–H171.Google Scholar
  104. 104.
    Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P, 2009 Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150: 2109–2117.PubMedCrossRefGoogle Scholar
  105. 105.
    Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL, 1980 The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 255: 10464–10471.Google Scholar
  106. 106.
    Hay RV, Pottenger LA, Reingold AL, Getz GS, Wissler RW, 1971 Degradation of I125-labelled serum low density lipoprotein in normal and estrogen-treated male rats. Biochem Biophys Res Commun 44: 1471–1477.PubMedCrossRefGoogle Scholar
  107. 107.
    Simpkins JW, Dykens JA, 2008 Mitochondrial mechanisms of estrogen neuroprotection. Brain Res Rev 57: 421–430.PubMedCrossRefGoogle Scholar
  108. 108.
    Lebesgue D, Chevaleyre V, Zukin RS, Etgen AM, 2009 Estradiol rescues neurons from global ischemia-induced cell death: Multiple cellular pathways of neuroprotection. Steroids 74: 555–561.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Guo XM, Lu X, Ren HM, Levin ER, Kassab GS, 2006 Estrogen modulates the mechanical homeostasis of mouse arterial vessels through nitric oxide. Am J Physiol 290: H1788–H1797.Google Scholar
  110. 110.
    Stirone C, Duckles SP, Krause DN, Procaccio V, 2005 Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 68: 959–965.PubMedCrossRefGoogle Scholar
  111. 111.
    Villa P, Sagnella F, Perri C, et al, 2008 Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11: 498–508.PubMedCrossRefGoogle Scholar
  112. 112.
    Yoon M, 2009 The role of PPARa in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARa actions. Pharmacol Res 60: 151–159.PubMedCrossRefGoogle Scholar
  113. 113.
    Al-Azzawi F, Palacios S, 2009 Hormonal changes during menopause. Maturitas 63: 135–137.PubMedCrossRefGoogle Scholar
  114. 114.
    Sarrel PM, 2002 Androgen deficiency: menopause and estrogen-related factors. Fertil Steril 77: 63–67.CrossRefGoogle Scholar
  115. 115.
    Bachmann GA, 2002 The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 77: 72–76.CrossRefGoogle Scholar
  116. 116.
    Tang V, Torregrosa C, Remesar X, Alemany M, 2001 Dietary oleoyl-estrone affects the growth rate of young rats. Eur J Nutr 40: 17–22.PubMedCrossRefGoogle Scholar
  117. 117.
    van den Belt K, Berckmans P, Vangenechten C, Verheyen R, Witters H, 2004 Comparative study on the in vitro in vivo estrogenic potencies of 17 beta-estradiol, estrone, 17 alpha- ethynylestradiol and nonylphenol. Aquat Toxicol 66: 183–195.PubMedCrossRefGoogle Scholar
  118. 118.
    Schlindler AE, Ebert A, Friedrich E, 1972 Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 35: 627–630.CrossRefGoogle Scholar
  119. 119.
    Remesar X, Fernández-López JA, Savall P, et al, 2002 Effect of oral oleoyl-estrone on adipose tissue composition in male rats. Int J Obesity 26: 1092–1102.CrossRefGoogle Scholar
  120. 120.
    Esteve M, Virgili J, Aguilar H, et al, 1999 Leptin enhances the synthesis of oleoyl-estrone from estrone in white adipose tissue. Eur J Nutr 38: 99–104.PubMedCrossRefGoogle Scholar
  121. 121.
    Vilà R, Cabot C, Villarreal L, Monegal A, et al, 2011 Oleoyl-estrone is a precursor of an estrone-derived ponderostat signal. J Steroid Biochem Mol Biol 124: 99–111.PubMedCrossRefGoogle Scholar
  122. 122.
    Levin BE, Patterson CM, 2005 Exercising the obese brain: Resetting the defended body weight. Endocrinology 146: 1674–1675.PubMedCrossRefGoogle Scholar
  123. 123.
    Grasa MD, Cabot C, Esteve M, et al, 2001 Daily oral oleoyl-estrone gavage induces a dose-dependent loss of fat in Wistar rats. Obes Res 9: 202–209.CrossRefGoogle Scholar
  124. 124.
    Buscemi S, Caimi G, Verga S, 1996 Resting metabolic rate and postabsorptive substrate oxidation in morbidly obese subjects before and after massive weight loss. Int J Obesity 20: 41–46.Google Scholar
  125. 125.
    Cottam DR, Mattar SG, Barinas-Mitchell E, et al, 2004 The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: Implications and effects of weight loss. Obes Surg 14: 589–600.PubMedCrossRefGoogle Scholar
  126. 126.
    Solá E, Jover A, López-Ruiz A, et al, 2009 Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes Surg 19: 571–576.PubMedCrossRefGoogle Scholar
  127. 127.
    Levin BE, Dunn-Meynell AA, 2002 Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. Am J Physiol 282: R46–R54.Google Scholar
  128. 128.
    Weigensberg MJ, Toledo-Corral CM, Goran MI, 2008 Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab 93: 1372–1378.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP, 2009 The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 94: 2692–2701.PubMedCrossRefGoogle Scholar
  130. 130.
    Vogelzangs N, Beekman ATF, Dik MG, et al, 2009 Late-life depression, cortisol, and the metabolic syndrome. Am J Geriat Psychiat 17: 716–721.CrossRefGoogle Scholar
  131. 131.
    van Steensel B, Jenster G, Damm K, Brinkmann AO, van Driel R, 1995 Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem 57: 465–478.PubMedCrossRefGoogle Scholar
  132. 132.
    Pasquali R, Vicennati V, Gambineri A, Pagotto U, 2008 Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. Int J Obesity 32: 1764–1779.CrossRefGoogle Scholar
  133. 133.
    Cheng MY, Sun G, Jin M, Zhao H, Steinberg GK, Sapolsky RM, 2009 Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral ischemia. J Cereb Blood Flow Metab 29: 130–136.PubMedCrossRefGoogle Scholar
  134. 134.
    Weiser MJ, Handa RJ, 2009 Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic-pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscince 159: 883–895.CrossRefGoogle Scholar
  135. 135.
    Grasa MM, Serrano M, Fernández-López JA, Alemany M, 2007 Corticosterone inhibits the lipid-mobilizing effects of oleoyl-estrone in adrenalectomized rats. Endocrinology 148: 4056–4063.CrossRefGoogle Scholar
  136. 136.
    Wolf G, 2002 Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60: 148–151.PubMedCrossRefGoogle Scholar
  137. 137.
    Wang M, 2005 The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab 2: 3.CrossRefGoogle Scholar
  138. 138.
    Macfarlane DP, Forbes S, Walker BR, 2008 Glucocorti-coids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197: 189–204.PubMedCrossRefGoogle Scholar
  139. 139.
    Napolitano A, Voice MW, Edwards CRW, Seckl JR, Chapman KE, 1998 11b-hydroxysteroid dehydrogenase 1 in adipocytes: Expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 64: 251–260.PubMedCrossRefGoogle Scholar
  140. 140.
    Tomlinson JW, Stewart PM, 2002 The functional consequences of 11b- hydroxysteroid dehydrogenase expression in adipose tissue. Horm Metabol Res 34: 746–751.CrossRefGoogle Scholar
  141. 141.
    Lee MJ, Fried SK, Mundt SS, Wang Y, Sullivan S, Stefanni A, Daugherty BL, Hermanowski-Vosatka A, 2008 Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity 16: 1178–1185.PubMedCrossRefGoogle Scholar
  142. 142.
    Stimson RH, Andersson J, Andrew R, et al, 2009 Cortisol release from adipose tissue by 11b-Hydroxysteroid Dehydrogenase type 1 in humans. Diabetes 58: 46–53.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Müller J, 1995 Aldosterone: The minority hormone of the adrenal cortex. Steroids 60: 2–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Hornsby PJ, 1995 Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann NY Acad Sci 774: 29–46.PubMedCrossRefGoogle Scholar
  145. 145.
    Havelock JC, Auchus RJ, Rainey WE, 2004 The rise in adrenal androgen biosynthesis: Adrenarche. Semin Reprod Med 22: 337–347.PubMedCrossRefGoogle Scholar
  146. 146.
    Reynolds RM, Walker BR, 2003 Human insulin resistance: the role of glucocorticoids. Diabet Obes Metabol 5: 5–12.CrossRefGoogle Scholar
  147. 147.
    Asensio C, Muzzin P, Rohner-Jeanrenaud F, 2004 Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obesity 28: S45–S52.CrossRefGoogle Scholar
  148. 148.
    Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jean-renaud F, Jeanrenaud B, 1997 Glucocorticoids as counterregulatory hormones of leptin - Toward an understanding of leptin resistance. Diabetes 46: 717–719.PubMedCrossRefGoogle Scholar
  149. 149.
    Ray DW, 1996 Molecular mechanisms of glucocorticoid resistance. J Endocrinol 149: 1–5.PubMedCrossRefGoogle Scholar
  150. 150.
    Ray PD, Foster DO, Lardy HA, 1964 Mode of action of glucocorticoids. I. Stimulation of gluconeogenesis independent of synthesis de novo of enzymes. J Biol Chem 239: 3396–3400.PubMedGoogle Scholar
  151. 151.
    May RC, Bailey JL, Mitch WE, Masud T, England BK, 1996 Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 49: 679–683.PubMedCrossRefGoogle Scholar
  152. 152.
    Tauchmanovà L, Pivonello R, di Somma C, Rossi R, de Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A, 2006 Bone demineralization and vertebral fractures in endogenous cortisol excess: Role of disease etiology and gonadal status. J Clin Endocrinol Metab 91: 1779–1784.PubMedCrossRefGoogle Scholar
  153. 153.
    Franchimont D, 2004 Overview of the actions of glucocorticoids on the immune response. A good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 1024: 124–137.PubMedGoogle Scholar
  154. 154.
    Kirschbaum C, Prüssner JC, Stone AA, et al, 1995 Persistent high cortisol responses to repeated psychological stress in a subpopulation of healthy men. Psychosomat Med 57: 468–474.CrossRefGoogle Scholar
  155. 155.
    Duclos M, Gouarne C, Bonnemaison D, 2003 Acute and chronic effects of exercise on tissue sensitivity to glucocorticoids. J Appl Physiol 94: 869–875.PubMedCrossRefGoogle Scholar
  156. 156.
    Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C, 1987 Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 156: 66–71.PubMedCrossRefGoogle Scholar
  157. 157.
    Wortsman J, Frank S, Cryer PE, 1984 Adrenomedullary response to maximal stress in humans. Am J Med 77: 779–784.PubMedCrossRefGoogle Scholar
  158. 158.
    Sutter-Dub MT, 2002 Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorti-coids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 67: 77–93.PubMedCrossRefGoogle Scholar
  159. 159.
    Kochakian CD, 1975 Definition of androgens and protein anabolic steroids. Pharmacol Ther B 1: 149–177.PubMedGoogle Scholar
  160. 160.
    Pasquali R, Vicennati V, Cacciari M, Pagotto U, 2006 The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann NY Acad Sci 1083: 111–128.PubMedCrossRefGoogle Scholar
  161. 161.
    Chrousos GP, 2000 The role of stress and the hypo-thalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obesity 24: Suppl 2: 50–55.CrossRefGoogle Scholar
  162. 162.
    Rosmond R, 2005 Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinol 30: 1–10.CrossRefGoogle Scholar
  163. 163.
    Hautanen A, Räikkönen K, Adlerkreutz H, 1997 Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med 241: 451–461.PubMedCrossRefGoogle Scholar
  164. 164.
    Livingstone DEW, Jones GC, Smith K, et al, 2000 Understanding the role of glucocorticoids in obesity: Tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141: 560–563.PubMedCrossRefGoogle Scholar
  165. 165.
    Wang MH, 2006 Tissue-specific glucocorticoid excess in the metabolic syndrome: 11b-HSD1 as a therapeutic target. Drug Develop Res 67: 567–569.CrossRefGoogle Scholar
  166. 166.
    Grasa MM, Cabot C, Fernández-López JA, Remesar X, Alemany M, 2001 Modulation of corticosterone availability to white adipose tissue of lean and obese Zucker rats by corticosteroid-binding globulin. Horm Metabol Res 33: 407–411.CrossRefGoogle Scholar
  167. 167.
    Barat P, Duclos M, Gatta B, Roger P, Mormede P, Moisan MP, 2005 Corticosteroid binding globulin gene polymorphism influences cortisol driven fat distribution in obese women. Obes Res 13: 1485–1490.PubMedCrossRefGoogle Scholar
  168. 168.
    Bledsoe RK, Montana VG, Stanley TB, et al, 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110: 93–105.PubMedCrossRefGoogle Scholar
  169. 169.
    Evans RM, 1988 The steroid and thyroid hormone receptor superfamily. Science 240: 889–895.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Chen SY, Wang J, Yu GQ, Liu WH, Pearce D, 1997 Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 272: 14087–14092.PubMedGoogle Scholar
  171. 171.
    Mitra R, Sapolsky RM, 2010 Expression of chimeric estrogen-glucocorticoid-receptor in the amygdala reduces anxiety. Brain Res 1342: 33–38.PubMedCrossRefGoogle Scholar
  172. 172.
    Mackem S, Baumann CT, Hager GL, 2001 A glucocorticoid/retinoic acid receptor chimera that displays cytoplasmic/nuclear translocation in response to retinoic acid. A real time sensing assay for nuclear receptor ligands. J Biol Chem 276: 45501–45504.PubMedGoogle Scholar
  173. 173.
    Genaro G, Franci CR, 2010 Cortisol influence on testicular testosterone secretion in domestic cat: An in vitro study. Pesq Vet Bras 30: 887–890.CrossRefGoogle Scholar
  174. 174.
    Dong Q, Salva A, Sottas CM, Niu EM, Holmes M, Hardy MR, 2004 Rapid glucocorticoid mediation of suppressed testosterone biosynthesis in male mice subjected to immobilization stress. J Androl 25: 973–981.PubMedCrossRefGoogle Scholar
  175. 175.
    MacAdams MR, White RH, Chipps BE, 1986 Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Int Med 104: 648–651.PubMedCrossRefGoogle Scholar
  176. 176.
    Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C, 1995 DHEA and peripheral androgen and estrogen formation: intracrinology. Ann NY Acad Sci 774: 16–28.PubMedCrossRefGoogle Scholar
  177. 177.
    Apostolova G, Schweizer RAS, Balazs Z, Kostadinova RM, Odermatt A, 2005 Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol 288: E957–E964.CrossRefGoogle Scholar
  178. 178.
    Browne ES, Wright BE, Porter JR, Svec F, 1992 Dehydroepiandrosterone. Antiglucocorticoid action in mice. Am J Med Sci 303: 366–371.PubMedCrossRefGoogle Scholar
  179. 179.
    Gong H, Jarzynka MJ, Cole TJ, et al, 2008 Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 68: 7386–7393.PubMedCrossRefGoogle Scholar
  180. 180.
    Weiser MJ, Foradori CD, Handa RJ, 2010 Estrogen receptor beta activation prevents glucocorticoid receptor-dependent effects of the central nucleus of the amygdala on behavior and neuroendocrine function. Brain Res 1336: 78–88.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Simoncini T, Maffei S, Basta G, et al, 2000 Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circul Res 87: 19–25.CrossRefGoogle Scholar
  182. 182.
    da Silva JP, 1999 Sex hormones and glucocorticoids: Interactions with the immune system. Ann NY Acad Sci 876: 102–118.PubMedCrossRefGoogle Scholar
  183. 183.
    Sheffield-Moore M, 2000 Androgens and the control of skeletal muscle protein synthesis. Ann Med 32: 181–186.PubMedCrossRefGoogle Scholar
  184. 184.
    Isozaki Y, Mitch WE, England BK, Price SR, 1996 Protein degradation and increased mRNAs encoding proteins of the ubiquitin-proteasome proteolytic pathway in BC3H1 myocytes require an interaction between glucocorticoids and acidification. Proc Nat Acad Sci USA 93: 1967–1971.PubMedCrossRefGoogle Scholar
  185. 185.
    Burt MG, Gibney J, Ho KKY, 2007 Protein metabolism in glucocorticoid excess: study in Cushing’s syndrome and the effect of treatment. Am J Physiol 292: E1426–E1432.Google Scholar
  186. 186.
    Goldstein RE, Rossetti L, Palmer BA, et al, 2002 Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo. Am J Physiol 283: E946–E957.Google Scholar
  187. 187.
    Monroe SE, Menon KMJ, 1977 Changes in reproductive hormone secretion during the climacteric and postmenopausal periods. Clin Obstet Gynecol 20: 113–122.PubMedCrossRefGoogle Scholar
  188. 188.
    Toth MJ, Tchernof A, Sites CK, Poehlman ET, 2000 Effect of menopausal status on body composition and abdominal fat distribution. Int J Obesity 24: 226–231.CrossRefGoogle Scholar
  189. 189.
    Franklin RM, Ploutz-Snyder L, Kanaley JA, 2009 Longitudinal changes in abdominal fat distribution with menopause. Metabolism 58: 311–315.PubMedCrossRefGoogle Scholar
  190. 190.
    Macdonald HM, New SA, Campbell MK, Reid DM, 2003 Longitudinal changes in weight in perimenopausal and early postmenopausal women: effects of dietary energy intake, energy expenditure, dietary calcium intake and hormone replacement therapy. Int J Obesity 27: 669–676.CrossRefGoogle Scholar
  191. 191.
    Piché ME, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J, Lemieux S, 2005 Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 54: 770–777.PubMedCrossRefGoogle Scholar
  192. 192.
    Motivala AA, Rose PA, Kim HM, et al, 2008 Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal women. J Nucl Cardiol 15: 510–517.PubMedCrossRefGoogle Scholar
  193. 193.
    Mesch VR, Siseles NO, Maidana PN, et al, 2008 Androgens in relationship to cardiovascular risk factors in the menopausal transition. Climacteric 11: 509–517.PubMedCrossRefGoogle Scholar
  194. 194.
    Korytkowski MT, Krug EI, Daly MA, DeRiso L, Wilson JW, Winters SJ, 2005 Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes? Metabolism 54: 1626–1631.PubMedCrossRefGoogle Scholar
  195. 195.
    Bonomo SM, Rigamonti AE, Giunta M, Galimberti D, Guaita A, Gagliano MG, Müller EE, Cella SG, 2009 Menopausal transition: A possible risk factor for brain pathologic events. Neurobiol Aging 30: 71–80.PubMedCrossRefGoogle Scholar
  196. 196.
    Kaye SA, Folsom AR, 1991 Is serum cortisol associated with body-fat distribution in postmenopausal women. Int J Obesity 15: 437–439.Google Scholar
  197. 197.
    Lindsay R, 1996 The menopause and osteoporosis. Obstet Gynecol 87: 16S–19S.PubMedCrossRefGoogle Scholar
  198. 198.
    Tenover JL, 1967 Testosterone and the aging male. J Androl 18: 103–106.Google Scholar
  199. 199.
    Delaporte E, 2008 Affections inflammatoires à médiation immunitaire et psoriasis. Ann Dermatol 135: Suppl 4: 269–274.Google Scholar
  200. 200.
    Karadag AS, Yavuz B, Ertugrul DT, et al, 2010 Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 49: 642–646.PubMedCrossRefGoogle Scholar
  201. 201.
    Reutrakul S, Hathout EH, Janner D, et al, 2004 Familial juvenile autoimmune hypothyroidism, pituitary enlargement, obesity, and insulin resistance. Thyroid 14: 311–319.PubMedCrossRefGoogle Scholar
  202. 202.
    Mauras N, DelGiorno C, Kollman C, et al, 2010 Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 95: 1060–1068.PubMedCrossRefGoogle Scholar
  203. 203.
    van Dijk SJ, Feskens EJM, Bos MB, et al, 2009 A saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression profile in adipose tissue of subjects at risk of metabolic syndrome. Am J Clin Nutr 90: 1656–1664.PubMedCrossRefGoogle Scholar
  204. 204.
    Fleming ME, Sales KM, Winslet MC, 2005 Diet and colorectal cancer: implications for the obese and devotees of the Atkins diet. Colorect Dis 7: 128–132.CrossRefGoogle Scholar
  205. 205.
    Jaggers JR, Sui XM, Hooker P, et al, 2009 Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 45: 1831–1838.PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Russo A, Autelitano M, Bisanti L, 2008 Metabolic syndrome and cancer risk. Eur J Cancer 44: 293–297.PubMedCrossRefGoogle Scholar
  207. 207.
    Tubiash HS, 1951 The anaerogenic effect of nitrates and nitrites on Gram-negative enteric bacteria. Am J Publ Hlth 41: 833–838.CrossRefGoogle Scholar
  208. 208.
    Dunca BB, Schmidt MI, 2001 Chronic activation of the innate immune system may underlie the metabolic syndrome. S Paulo Med J 119: 122–127.CrossRefGoogle Scholar
  209. 209.
    Cani PD, Possemiers S, van de Wiele T, et al, 2009 Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091–1103.PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI, 2006 Human gut microbes associated with obesity. Nature 444: 1022–1023.PubMedCrossRefGoogle Scholar
  211. 211.
    Najzer M, Seeley RJ, 2006 Obesity and gut flora. Nature 444: 1009–1010.CrossRefGoogle Scholar
  212. 212.
    Delzenne NM, Cani PD, 2010 Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: Potential interest of prebiotics. Int Dairy J 20: 277–280.CrossRefGoogle Scholar
  213. 213.
    Manco M, Putignani L, Bottazzo GF, 2010 Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817–844.PubMedCrossRefGoogle Scholar
  214. 214.
    Creely SJ, McTernan PG, Kusminski CM, et al, 2007 Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol 292: E740–E747.CrossRefGoogle Scholar
  215. 215.
    Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY, 2007 Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol 292: G590-G598.Google Scholar
  216. 216.
    Hales CN, Barker DJP, 2001 The thrifty phenotype hypothesis. Br Med Bull 60: 5–20.PubMedCrossRefGoogle Scholar
  217. 217.
    Flodmark CE, 2002 Thrifty genotypes and phenotypes in the pathogenesis of early-onset obesity. Acta Paediatr 91: 737–738.PubMedCrossRefGoogle Scholar
  218. 218.
    Sclafani A, Springer D, 1976 Dietary obesity in adult rats: Similarities to hypothalamic and human obesity syndromes. Physiol Behav 17: 461–471.PubMedCrossRefGoogle Scholar
  219. 219.
    Prats E, Monfar M, Iglesias R, Castellà J, Alemany M, 1989 Energy intake of rats fed a cafeteria diet. Physiol Behav 45: 263–272.PubMedCrossRefGoogle Scholar
  220. 220.
    Rogers PJ, 1985 Returning ‘cafeteria- fed’ rats to a chow diet: negative contrast and effects of obesity on feeding behaviour. Physiol Behav 35: 493–499.PubMedCrossRefGoogle Scholar
  221. 221.
    Welle SL, Amatruda JM, Forbes GB, Lockwood DH, 1984 Resting metabolic rates of obese women after rapid weight loss. J Clin Endocrinol Metab 59: 113–122.CrossRefGoogle Scholar
  222. 222.
    Brownell KD, Greenwood MRC, Stellar E, Shrager EE, 1986 The effects of repeated cycles of weight loss and regain in rats. Physiol Behav 38: 459–464.PubMedCrossRefGoogle Scholar
  223. 223.
    Kirschner MA, Schneider G, Ertel NH, Gorman J, 1988 An 8-year experience with a very -low -calorie formula diet for control of major obesity. Int J Obesity 12: 69–80.Google Scholar
  224. 224.
    van Itallie TB, Kral JG, 1981 The dilemma of morbid obesity. J Am Med Assoc 246: 999–1003.CrossRefGoogle Scholar
  225. 225.
    Dulloo AG, Girardier L, 1992 Influence of dietary composition on energy expenditure during recovery of body weight in the rat. Implications for catch up growth and obesity relapse. Metabolism 41: 1336–1342.PubMedGoogle Scholar
  226. 226.
    Bradley P, 1978 The ponderostat and a physiological model of obesity. Am J Clin Nutr 31: 1976–1978.Google Scholar
  227. 227.
    Dube MG, Xu B, Crowley WR, Kalra PS, Kalra SP, 1994 Evidence that neuropeptide Y is a physiological signal for normal food intake. Brain Res 646: 341–344.PubMedCrossRefGoogle Scholar
  228. 228.
    Yang L, Scott KA, Hyun J, et al, 2009 Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J Neurosci 29: 179–190.PubMedPubMedCentralCrossRefGoogle Scholar
  229. 229.
    Benoit S, Schwartz M, Baskin D, Woods SC, Seeley RJ, 2000 CNS melanocortin system involvement in the regulation of food intake. Horm Behav 37: 299–305.PubMedCrossRefGoogle Scholar
  230. 230.
    Ellacott KLJ, Cone RD, 2006 The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Phil Trans Roy Soc Lond B 361: 1265–1274.CrossRefGoogle Scholar
  231. 231.
    Raffin-Sanson ML, de Keyzer Y, Bertagna X, 2003 Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol 149: 79–90.PubMedCrossRefGoogle Scholar
  232. 232.
    Costin GE, Hearing VJ, 2007 Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 21: 976–994.PubMedCrossRefGoogle Scholar
  233. 233.
    Schwartz RA, 1994 Acanthosis nigricans. J Am Acad Dermatol 31: 1–19.PubMedCrossRefGoogle Scholar
  234. 234.
    Kahn CR, Flier JS, Bar RS, et al, 1976 The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294: 739–745.PubMedGoogle Scholar
  235. 235.
    López M, Lage R, Tung CL, et al, 2007 Orexin expression is regulated by alpha-melanocyte stimulating hormone. J Neuroendocrinol 19: 703–707.PubMedPubMedCentralCrossRefGoogle Scholar
  236. 236.
    Rodgers RJ, Halford JCG, Nunes de Souza RL, et al, 2000 Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul Peptides 96: 71–84.CrossRefGoogle Scholar
  237. 237.
    Salin-Pascual RI, 2001 The role of the hypothalamic neuropeptides hypocretin/orexin in the sleep-wake cycle. Isr Med Assoc J 3: 144–146.PubMedGoogle Scholar
  238. 238.
    Bass J, Turek FW, 2005 Sleepless in America. A pathway to obesity and the metabolic syndrome? Arch Intern Med 165: 15–16.PubMedGoogle Scholar
  239. 239.
    Choi KM, Lee JS, Park HS, Baik SH, Choi DS, Kim SM, 2008 Relationship between sleep duration and the metabolic syndrome:Korean National Health Nutrition Survey 2001. Int J Obesity 32: 1091–1097.CrossRefGoogle Scholar
  240. 240.
    Donga E, van Dijk M, van Dijk JG, et al, 2010 A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab 95: 2963–2968.PubMedCrossRefGoogle Scholar
  241. 241.
    Rosa Neto JC, Lira FS, Venancio DP, et al, 2010 Sleep deprivation affects inflammatory marker expression in adipose tissue. Lip Hlth Dis 9: 125.CrossRefGoogle Scholar
  242. 242.
    Hasler G, Buysse DJ, Klaghofer R, et al, 2004 The association between short sleep duration and obesity in young adults: A 13-year prospective study. Sleep 27: 661–666.PubMedCrossRefGoogle Scholar
  243. 243.
    Nielsen LS, Danielsen KV, Sørensen TIA, 2011 Short sleep duration as a possible cause of obesity: critical analysis of the epidemiological evidence. Obes Rev 12: 78–92.PubMedCrossRefGoogle Scholar
  244. 244.
    Resta O, Barbaro MPF, Bonfitto P, et al, 2003 Low sleep quality and daytime sleepiness in obese patients without obstructive sleep apnoea syndrome. J Intern Med 253: 536–543.PubMedCrossRefGoogle Scholar
  245. 245.
    Fukagawa K, Sakata T, Yoshimatsu H, Fujimoto K, Uchimura K, Asano C, 1992 Advance shift of feeding circadian rhythm induced by obesity progression in Zucker rats. Am J Physiol 263: R1169–R1175.PubMedGoogle Scholar
  246. 246.
    Dickmeis T, Lahiri K, Nica G, et al, 2007 Glucocorticoids play a key role in circadian cell cycle rhythms. PLoS Biol 5: 854–864.CrossRefGoogle Scholar
  247. 247.
    Dallman MF, Viau VG, Bhatnagar S, Gomez F, Laugero K, Beli ME, 2011 Corticotropin-releasing factor, corticosteroids, stress, and sugar: energy balance, the brain and behavior. Hormones Brain and Behavior 1: 571–631.Google Scholar
  248. 248.
    Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB, 2005 Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 493: 63–71.PubMedCrossRefGoogle Scholar
  249. 249.
    López M, Varela L, Vázquez MJ, et al, 2010 Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001–1008.PubMedPubMedCentralCrossRefGoogle Scholar
  250. 250.
    Handa RJ, Burgess LH, Kerr JE, O’Keefe JA, 1994 Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. Horm Behav 28: 464–476.PubMedCrossRefGoogle Scholar
  251. 251.
    Kiss A, Jezova D, Aguilera G, 1994 Activity of the hypothalamic-pituitary-adrenal axis and sympathoadrenal system during food and water deprivation in the rat. Brain Res 663: 84–92.PubMedCrossRefGoogle Scholar
  252. 252.
    Yoshimatsu H, Niijima A, Oomura Y, Katafuchi T, 1988 Lateral and ventromedial hypothalamic influences on hepatic autonomic nerve activity in the rat. Brain Res Bull 21: 239–244.PubMedCrossRefGoogle Scholar
  253. 253.
    Atrens DM, Holmes LJ, Jirasek M, Siviy SM, Solowij N, 1987 Hypothalamic modulation of thermogenesis and energy substrate utilization. Brain Res Bull 18: 303–308.PubMedCrossRefGoogle Scholar
  254. 254.
    Kuo JJ, Silva AA, Hall JE, 2003 Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 41: 768–774.PubMedCrossRefGoogle Scholar
  255. 255.
    Wise RA, 2006 Role of brain dopamine in food reward and reinforcement. Phil Trans Roy Soc Lond B 361: 1149–1158.CrossRefGoogle Scholar
  256. 256.
    Meguid MM, Fetissov SO, Varma M, et al, 2000 Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 16: 843–857.PubMedCrossRefGoogle Scholar
  257. 257.
    Kelley AE, Baldo BA, Pratt WE, Will MJ, 2005 Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward. Physiol Behav 86: 773–795.PubMedCrossRefGoogle Scholar
  258. 258.
    Grill HJ, 2006 Distributed neural control of energy balance: Contributions from hindbrain and hypothalamus. Obesity 14: Suppl 5: 216–221.CrossRefGoogle Scholar
  259. 259.
    Cummings DE, Overduin J, 2007 Gastrointestinal regulation of food intake. J Clin Invest 117: 13–23.PubMedPubMedCentralCrossRefGoogle Scholar
  260. 260.
    Colombani AL, Carneiro L, Benani A, et al, 2009 Enhanced hypothalamic glucose sensing in obesity: Alteration of redox signaling. Diabetes 58: 2189–2197.PubMedPubMedCentralCrossRefGoogle Scholar
  261. 261.
    Horn EM, Waldrop TG, 1997 Oxygen-sensing neurons in the caudal hypothalamus and their role in cardiorespiratory control. Resp Physiol 110: 219–228.CrossRefGoogle Scholar
  262. 262.
    Mason WT, 1980 Supraoptic neurones of rat hypothalamus are osmosensitive. Nature 287: 154–157.PubMedCrossRefGoogle Scholar
  263. 263.
    Rothwell NJ, Stock MJ, 1987 Effect of diet and fenfluramine on thermogenesis in the rat: Possible involvement of serotonergic mechanisms. Int J Obesity 11: 319–324.Google Scholar
  264. 264.
    Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR, 1998 A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 125: 301–308.PubMedPubMedCentralCrossRefGoogle Scholar
  265. 265.
    Levine LR, Rosenblatt S, Bosomworth J, 1987 Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obesity 11: 185–190.Google Scholar
  266. 266.
    Nielsen JA, Chapin DS, Johnson JL, Torgersen LK, 1992 Sertraline, a serotonin uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 55:Suppl 1: 185–188.CrossRefGoogle Scholar
  267. 267.
    Yu S, Holsboer F, Almeida OFX, 2008 Neuronal actions of glucocorticoids: Focus on depression. J Steroid Biochem Mol Biol 108: 300–309.PubMedCrossRefGoogle Scholar
  268. 268.
    Porter RJ, Gallagher P, Watson S, Young AH, 2004 Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacol 173: 1–17.CrossRefGoogle Scholar
  269. 269.
    Gómez R, Navarro M, Ferrer B, et al, 2002 A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612–9617.PubMedCrossRefGoogle Scholar
  270. 270.
    Boyd ST, Fremming BA, 2005 Rimonabant - A selective CB1 antagonist. Ann Pharmacother 39: 684–690.PubMedCrossRefGoogle Scholar
  271. 271.
    Caul WF, Jones JR, Barrett RJ, 1988 Amphetamine’s effects on food consumption and body weight. The role of adaptive processes. Behav Neurosci 102: 441–450.PubMedGoogle Scholar
  272. 272.
    Bukowiecki L, Follea N, Jahjah L, 1982 Ephedrine, a potential slimming drug, directly stimulates thermo-genesis in brown adipocytes via β-adrenoreceptors. Int J Obesity 6: 343–350.Google Scholar
  273. 273.
    Michel C, Cabanac M, 1999 Effects of dexamethasone on the body weight set point of rats. Physiol Behav 68: 145–150.PubMedCrossRefGoogle Scholar
  274. 274.
    Messerli FH, Bell DSH, Fonseca V, et al, 2007 Body weight changes with beta-blocker use: Results from GEMINI. Am J Med 120: 610–615.PubMedCrossRefGoogle Scholar
  275. 275.
    Patten SB, Williams JVA, Lavorato DH, Brown L, McLaren L, Eliasziw M, 2009 Major depression, anti-depressant medication and the risk of obesity. Psychoter Psychosomat 78: 182–186.CrossRefGoogle Scholar
  276. 276.
    Vanina Y, Podolskaya A, Sedky K, et al, 2002 Body weight changes associated with psychopharmacology. Psychiat Serv 53: 842–847.CrossRefGoogle Scholar
  277. 277.
    Fornari A, Pedrazzi P, Lippi G, Picciotto MR, Zoli M, Zini I, 2007 Nicotine withdrawal increases body weight, neuropeptide Y and Agouti-related protein expression in the hypothalamus and decreases uncoupling protein-3 expression in the brown adipose tissue in high-fat fed mice. Neurosci Lett 411: 72–76.PubMedCrossRefGoogle Scholar
  278. 278.
    Keck PE, McElroy SL, 2003 Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiat 64: 1426–1435.CrossRefGoogle Scholar
  279. 279.
    Mussell MP, Mitchell JE, de Zwaan M, Crosby RD, Seim HC, Crow SJ, 1996 Clinical characteristics associated with binge eating in obese females: A descriptive study. Int J Obesity 20: 324–331.Google Scholar
  280. 280.
    Fandiño J, Moreira RO, Preissler C, et al, 2010 Impact of binge eating disorder in the psychopathological profile of obese women. Comprehens Psychiat 51: 110–114.CrossRefGoogle Scholar
  281. 281.
    Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M, 2000 The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiat 57: 659–665.PubMedCrossRefGoogle Scholar
  282. 282.
    Boggiano MM, Artiga AI, Pritchett CE, Chandler-Laney PC, Smith ML, Eldridge AJ, 2007 High intake of palatable food predicts binge-eating independent of susceptibility to obesity: an animal model of lean vs obese binge-eating and obesity with and without binge-eating. Int J Obesity 31: 1357–1367.CrossRefGoogle Scholar
  283. 283.
    Dallman MF, Pecoraro N, Akana SF, et al, 2003 Chronic stress and obesity: A new view of “comfort food”. Proc Nat Acad Sci USA 100: 11696–11701.PubMedCrossRefGoogle Scholar
  284. 284.
    Kandiah J, Yake M, Jones J, Meyer M, 2006 Stress influences appetite and comfort food preferences in college women. Nutr Res 26: 118–123.CrossRefGoogle Scholar
  285. 285.
    Belsare PV, Watve MG, Ghaskadbi SS, Bhat DS, Yajnik CS, Jog M, 2010 Metabolic syndrome: Aggression control mechanisms gone out of control. Med Hypoth 74: 578–589.CrossRefGoogle Scholar
  286. 286.
    Alemany M, 2011 The defense of adipose tissue against excess substrate-induced hyperthrophia: Immune system cell infiltration and arrested metabolic activity. J Clin Endocrinol Metab 96: 66–68.PubMedCrossRefGoogle Scholar
  287. 287.
    Alemany M, 2012 Do the interactions between gluco-corticoids and sex hormones regulate the development of the metabolic syndrome? Front Endocrinol 3: 27.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2012

Authors and Affiliations

  1. 1.Department of Nutrition and Food Science, Faculty of BiologyUniversity of BarcelonaBarcelonaSpain
  2. 2.CIBER Obesity and NutritionInstitute of Health Carlos IIISpain

Personalised recommendations